Keywords: SkyePharma, Flutiform, Abbott, US marketing rights

SkyePharma regains US marketing rights to Flutiform from Abbott

Article | 23 August 2010

Print This

Shares of UK drug formulation specialist SkyePharma (SKP: L) fell by as much as 5% to 38 pence early on Friday – but ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in